ZA201507628B - Monoclonal antibodies against antithrombin beta complexed with heparin - Google Patents

Monoclonal antibodies against antithrombin beta complexed with heparin

Info

Publication number
ZA201507628B
ZA201507628B ZA2015/07628A ZA201507628A ZA201507628B ZA 201507628 B ZA201507628 B ZA 201507628B ZA 2015/07628 A ZA2015/07628 A ZA 2015/07628A ZA 201507628 A ZA201507628 A ZA 201507628A ZA 201507628 B ZA201507628 B ZA 201507628B
Authority
ZA
South Africa
Prior art keywords
heparin
monoclonal antibodies
antibodies against
complexed
against antithrombin
Prior art date
Application number
ZA2015/07628A
Other languages
English (en)
Inventor
Timothy Myles
Terry Hermiston
John E Murphy
Ye Jin
Uwe Gritzan
Michael Strerath
Frank Dittmer
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201507628(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA201507628B publication Critical patent/ZA201507628B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2015/07628A 2013-03-14 2015-10-13 Monoclonal antibodies against antithrombin beta complexed with heparin ZA201507628B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14
PCT/US2014/029541 WO2014153195A1 (en) 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin

Publications (1)

Publication Number Publication Date
ZA201507628B true ZA201507628B (en) 2017-11-29

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/07628A ZA201507628B (en) 2013-03-14 2015-10-13 Monoclonal antibodies against antithrombin beta complexed with heparin

Country Status (18)

Country Link
US (4) US9593166B2 (https=)
EP (1) EP2970500A1 (https=)
JP (1) JP2016519081A (https=)
KR (1) KR20150127202A (https=)
CN (1) CN105229033B (https=)
AR (1) AR095499A1 (https=)
AU (1) AU2014236198A1 (https=)
BR (1) BR112015021399A2 (https=)
CA (1) CA2916421A1 (https=)
HK (1) HK1215261A1 (https=)
MX (1) MX2015012441A (https=)
PE (1) PE20160533A1 (https=)
RU (1) RU2015143696A (https=)
SG (1) SG11201506886TA (https=)
TW (1) TW201529602A (https=)
UY (1) UY35457A (https=)
WO (1) WO2014153195A1 (https=)
ZA (1) ZA201507628B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506886TA (en) * 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
US10356677B2 (en) * 2014-05-19 2019-07-16 Nokia Solutions And Networks Oy Re-establishment procedure in dual connectivity networks
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH0694713A (ja) * 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット
JPH07238099A (ja) 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
DK0912738T3 (da) 1996-05-22 2008-11-17 Viventia Biotech Inc Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
EP0912728A1 (en) 1996-05-31 1999-05-06 MediGene Aktiengesellschaft Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
AU782069B2 (en) 1999-05-13 2005-06-30 Gtc Biotherapeutics, Inc. Transgenically produced antithrombin III and mutants thereof
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2003089575A2 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
WO2003101398A2 (en) 2002-05-31 2003-12-11 University Of Utah Research Foundation Variants of antithrombin iii
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
CA2518371A1 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
US8551920B2 (en) 2005-02-01 2013-10-08 Morpho Sys AG Libraries and methods for isolating antibodies
US8741844B2 (en) 2007-07-20 2014-06-03 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
CA2855353C (en) 2011-11-11 2021-01-19 Sio2 Medical Products, Inc. Passivation, ph protective or lubricity coating for pharmaceutical package, coating process and apparatus
SG11201506886TA (en) * 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
RU2015143696A (ru) 2017-04-19
MX2015012441A (es) 2016-08-08
TW201529602A (zh) 2015-08-01
UY35457A (es) 2014-10-31
JP2016519081A (ja) 2016-06-30
AU2014236198A1 (en) 2015-10-15
US9593166B2 (en) 2017-03-14
BR112015021399A2 (pt) 2017-07-18
PE20160533A1 (es) 2016-06-09
US10144784B2 (en) 2018-12-04
SG11201506886TA (en) 2015-09-29
US20140271661A1 (en) 2014-09-18
US20160024222A1 (en) 2016-01-28
CA2916421A1 (en) 2014-09-25
AR095499A1 (es) 2015-10-21
CN105229033A (zh) 2016-01-06
US20180244799A1 (en) 2018-08-30
CN105229033B (zh) 2019-04-23
EP2970500A1 (en) 2016-01-20
US20140271660A1 (en) 2014-09-18
KR20150127202A (ko) 2015-11-16
US9908942B2 (en) 2018-03-06
HK1215261A1 (zh) 2016-08-19
WO2014153195A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
ZA201808451B (en) Anti-fcrh5 antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
PL3071595T3 (pl) Humanizowane przeciwciało przeciw kalikreinie-2
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
SG11201509361TA (en) Novel antibodies
EP2931314A4 (en) CHIMERIC AND HUMANIZED ANTI-HISTON ANTIBODIES
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
ZA201601437B (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
ZA201507628B (en) Monoclonal antibodies against antithrombin beta complexed with heparin
EP2970445A4 (en) Humanized anti-n2 antibodies
IL245488B (en) Anti- ccl17 antibodies
ZA201508081B (en) Monoclonal antibody directed against cxcr5
PL2970503T3 (pl) Przeciwciała monoklonalne przeciw-(+) --metamfetaminie
GB201318283D0 (en) Antibodies